Shamburg News · 8-K filed Nov 12, 2026, 4:11 PM EST

Pliant Therapeutics Reports Q3 2026 Net Loss of $24.4 Million; Cash Funds Operations to Mid-2028

PLRX · PLIANT THERAPEUTICS, INC.

  • Earnings
  • Materiality: high

Pliant Therapeutics reported financial results for the period ended September 30, 2026, with a net loss of $24.4 million, or $0.39 per share, compared with $26.3 million a year earlier. Research and development expenses were $17.9 million and general and administrative expenses were $7.8 million for the quarter. The company had cash, cash equivalents and short-term investments of $142.6 million, which it expects will fund operations to mid-2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001746473-26-000127.

Written from the filing by Shamburg Markets. Figures are as reported by the company.